13D Filing: Orbimed Israel Biofund Gp Limited Partnership and Medigus Ltd.

Page 3 of 10

Page 3 of 10 – SEC Filing

SCHEDULE 13D
CUSIP No.  58471G102
Page 3 of 10 Pages
1
NAME OF REPORTING PERSONS
OrbiMed Israel GP Ltd.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a) o
(b) o
3
SEC USE ONLY
4
SOURCE OF FUNDS (See Instructions)
N/A
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
State of Israel
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
7
SOLE VOTING POWER
0
8
SHARED VOTING POWER
7,407,282  (1)
9
SOLE DISPOSITIVE POWER
0
10
SHARED DISPOSITIVE POWER
7,407,282  (1)
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
7,407,282  (1)
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
7.86% (2)
14
TYPE OF REPORTING PERSON (See Instructions)
CO
(1)
Includes 3,000,000 Ordinary Shares (as defined below) evidenced by 60,000 American Depositary Shares (“ADSs”) and 1,054,524 Ordinary Shares issuable upon the exercise of warrants.
(2)
This percentage is calculated based upon 93,128,584 of the Issuer’s Ordinary Shares outstanding, as reported in the Issuer’s Prospectus Supplement filed with the Securities Exchange Commission (the “SEC”) on March 27, 2017.

Follow Medigus Ltd. (NASDAQ:MDGS)

Page 3 of 10